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Abstract
Extracts of Chinese red yeast rice (RYR, a traditional dietary seasoning of Monascus purpureus)
contains several active ingredients including lovastatin, and several trials of its possible lipid-
lowering effects have been conducted. This meta-analysis assesses the effectiveness and safety of
RYR preparations on lipid modification in primary hyperlipidemia. We included randomized
controlled trials testing RYR preparation, compared with placebo, no treatment, statins, or other
active lipid-lowering agents in people with hyperlipidemia through searching PubMed, CBMdisk,
TCMLARS, the Cochrane Library, and AMED up to December 2004. Ninety-three randomized
trials (9625 participants) were included and three RYR preparations (Cholestin, Xuezhikang and
Zhibituo) were tested. The methodological quality of trial reports was generally low in terms of
generation of the allocation sequence, allocation concealment, blinding, and intention-to-treat. The
combined results showed significant reduction of serum total cholesterol levels (weighted mean
difference -0.91 mmol/L, 95% confidence interval -1.12 to -0.71), triglycerides levels (-0.41 mmol/
L, -0.6 to -0.22), and LDL-cholesterol levels (-0.73 mmol/L, -1.02 to -0.043), and increase of HDL-
cholesterol levels (0.15 mmol/L, 0.09 to 0.22) by RYR treatment compared with placebo. The lipid
modification effects appeared to be similar to pravastatin, simvastatin, lovastatin, atorvastatin, or
fluvastatin. Compared with non-statin lipid lowering agents, RYR preparations appeared superior
to nicotinate and fish oils, but equal to or less effective than fenofibrate and gemfibrozil. No
significant difference in lipid profile was found between Xuezhikang and Zhibituo. RYR preparations
were associated with non-serious adverse effects such as dizziness and gastrointestinal discomfort.
Current evidence shows short-term beneficial effects of RYR preparations on lipid modification.
More rigorous trials are needed, and long-term effects and safety should be investigated if RYR
preparations are to be recommended as one of the alternative treatments for primary
hyperlipidemia.
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Background
Red yeast rice (RYR) is a traditional Chinese cuisine and
medicinal agent prepared by using Monascus purpureus fer-
mented with rice, which has been recorded in ancient Chi-
nese pharmacopoeia Ben Cao Gang Mu-Dan Shi Bu Yi
during the Ming Dynasty (1368–1644)[1]. The extracts
from RYR contain starch, sterols, isoflavones, and
monounsaturated fatty acids, and other compounds [2,3];
depending on Monascus  strains used and fermentation
conditions, it may contain polyketides called monacolins
[4]. Monacolin K is lovastatin, which is a commonly pre-
scribed lipid-lowering drug. Several randomized clinical
trials have indicated beneficial effects of the RYR prepara-
tions including Xuezhikang and Zhibituo in the treatment
of hyperlipidemia [5-9]. Xuezhikang has been in clinical
use as a Chinese proprietary medicine in China and has
recently been marketed in several European countries
including Norway and Italy. As these preparations contain
different compositions and concentration of lovastatin,
evaluation of their effectiveness and safety from clinical
trials is warranted.
People with hyperlipidemia have responded well to the
lipid-lowering agents including HMG-CoA reductase
inhibitors (statins), fibrates, nicotinic acids, and n-3 fatty
acids [10]. However, long-term safety and potential drug
interaction between statins and other hypolipidemic
agents may become problematic [11-13]. Nowadays,
many people would like to use naturaceuticals instead of
chemical drugs. A previous systematic review identified
four randomized trials of the lipid-lowering effects of RYR
and concluded a lack of sufficient clinical research to sup-
port their efficacy [14]. The objective of this review is to
assess the beneficial effects of lipid modification and
safety of RYR preparations for their use in people with pri-
mary hyperlipidemia.
Methods
Search strategy
To identify relevant studies, we searched the following
databases up to December 2004: The Cochrane Library,
PubMed, Chinese Biomedical Database (CBMdisk), Tra-
ditional Chinese Medical Literature Analysis and Retrieval
System (TCMLARS), and the Allied and Complementary
Medicine Database (AMED). We used the search terms
'red yeast rice, Monascus purpureus, Xuezhikang, Cholestin,
Hypochol, Hypocol, Lipascor', combined with 'hyperlipi-
demia, hypercholesterolemia, dyslipidemia, hypertriglyc-
eridemia, hyperlipoproteinemia', and limited our search
to clinical trials. Depending on the database, various com-
binations of both MeSH terms and the free text terms were
used, but no limitation with regard to language and report
type. We also screened the reference lists of identified
papers and review articles, and contacted pharmaceutical
companies.
Inclusion criteria
We included randomized clinical trials comparing RYR vs.
placebo, no intervention, or established lipid-lowering
agents in individuals with primary hyperlipidemia on
outcomes of lipid profile and adverse effects. Eligible trials
had to include adult participants meeting the National
Cholesterol Education Programme diagnostic criteria of
hyperlipidemia [15] and excluded secondary causes such
as hypothyroidism, familial hypercholesterolemia, diabe-
tes mellitus, liver or kidney diseases. Trials comparing dif-
ferent RYR preparations were included, but trials
comparing different dosage of RYR preparations or com-
paring RYR with other herbal medicines were excluded.
Validity assessment
The methodological quality of trials was assessed using
the generation of the allocation sequence, the allocation
concealment, double blinding, and withdrawals/drop-
outs [16-19].
Data abstraction
One author (JL) extracted data and another author (JZ)
cross-checked the data, and any disagreement was
resolved by consensus. The following study characteristics
were abstracted from the trials: design, participants and
diagnosis, intervention regimen, and outcome measures.
Data synthesis
We used the statistical package (RevMan 4.2) provided by
the Cochrane Collaboration for data analyses. Dichoto-
mous data were presented as relative risk (RR) and contin-
uous outcomes as weighted mean difference (WMD),
both with 95% confidence interval (CI). We assessed data
by both random effects and fixed effect analyses, but
reported the random effect analysis if the heterogeneity
was significant, which was assessed by the I2 statistic and
used P < 0.10 as significance limit [20].
Results
Included trials
We identified 647 records on RYR preparations from elec-
tronic and manual searches. By reading titles and
abstracts, we excluded 275 citations that were clearly
duplicates, review articles, or non-clinical studies. A total
of 372 articles published in Chinese or English were
retrieved for further assessment. Of these, 279 articles
were excluded because they were non-controlled clinical
studies or randomized trials with different research objec-
tives. Two of these were ongoing placebo-controlled trials
testing 'Hypocol' in Norway and 'Lipolysar' in Italy [21],
but data were not available while writing this report. In
total, 93 randomized clinical trials [6-8,22-111] were
identified and they reported to allocate participants with
primary hyperlipidemia (n = 9625) randomly to RYR
preparation or no treatment (2 trials), placebo (8 trials),Chinese Medicine 2006, 1:4 http://www.cmjournal.org/content/1/1/4
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statins (37 trials), other lipid-lowering agents (42 trials),
or to a different RYR preparation (7 trials), in which three
trials had more than two arms. The 93 trials were parallel
group trials, and 91 were published in Chinese and two
published in English [7,49]. Three RYR preparations were
tested in the included trials: The RYR dietary supplement
(Cholestin), and the Chinese proprietary medicines
Xuezhikang and Zhibituo. Their constituents, dosages, and
treatment regimens are listed in Table 1. All trials reported
lipid profile outcome and 77 trials also reported adverse
effects.
Methodological quality of included trials
Of the 93 trials, only three trials reported the methods to
generate the allocation sequence (random number table
or permuted blocks) [7,32,70], and two trials were
assessed as having adequate concealment [7,29]. Five tri-
als applied double-blinding [7,25-27,30], and three trials
blinded the outcome assessors [29,51,106]. One trial
reported prior sample size estimation and information on
withdrawal/dropout [7], but no trial mentioned inten-
tion-to-treat analysis. Accordingly, the included trials had
generally low methodological quality. All trials provided
baseline data for the comparability among groups. The
average sample size of the randomized trials was 103,
ranging from 28 to 450 participants per trial.
Total cholesterol (TC) levels (Tables 2 and 3)
The three RYR preparations significantly reduced serum
TC levels and the effect was reached at four weeks after the
treatment and remained stable until 12 weeks (Figure 1).
The percentage of TC level reduction was 16% for choles-
tin, 19%–44% for Xuezhikang, and 13%–21% for Zhi-
bituo (Table 2). Compared with no treatment, Zhibituo
showed a reduction of serum TC levels (WMD -1.27
mmol/L; 95% CI -1.50 to -1.05; 2 trials, n = 112) [22,23].
Compared with placebo, significant reduction of serum
TC levels was found for Cholestin (WMD -1.04 mmol/L;
95% CI -1.41 to -0.67; 1 trial, n = 83) [7], Xuezhikang
(WMD -1.04 mmol/L; 95% CI -1.46 to -0.62; 4 trials, n =
323) [8,24-26], and Zhibituo (WMD -0.80 mmol/L; 95%
CI -1.03 to -0.57; 3 trials, n = 283) [27-29]. There was no
significant heterogeneity among the trials (I2 statistic test)
(Table 3). Different treatment duration showed similar
effect of RYR preparations in reducing TC levels compared
with placebo by 4 weeks (WMD -0.96 mmol/L; 95% CI -
1.49 to -0.43; 2 trials, n = 113) [25,26], 6 weeks (WMD -
0.61; 95% CI -1.0 to -0.22; 2 trials, n = 78) [27,28], 8
weeks (WMD -1.06; 95% CI -1.39 to -0.73; 5 trials, n =
406) [7,8,24-26], and 12 weeks (WMD -1.04; 95% CI -
1.41 to -0.67; 1 trial, n = 83) [7].
Xuezhikang and Zhibituo were compared with simvastatin,
pravastatin, lovastatin, atorvastatin, or fluvastatin in 37
trials. There was no statistically significant difference in
TC levels between RYR preparation and statins except for
one trial, in which Xuezhikang was less effective than fluv-
astatin (WMD 0.48 mmol/L; 95% CI 0.24 to 0.72; n =
118) [55]. One trial presented data as number of subjects
with at least 10% reduction of TC levels, and it showed no
difference between Xuezhikang and lovastatin (64/69 vs.
68/76; RR 1.04; 95% CI 0.94 to 1.15) [64]. In these trials,
Xuezhikang was used at dosage of 1.2 g/day (containing 10
mg of lovastatin), Zhibituo at 3.15 g/day (containing 9 mg
of lovastatin), simvastatin at 10–20 mg/day, pravastatin at
10 mg/day, lovastatin at 20 mg/day, atorvastatin 10 mg/
day, and fluvastatin 20 mg/day.
Compared with non-statin lipid-lowering agents,
Xuezhikang was more effective in lowering TC levels than
inositol nicotinate (WMD -0.56 mmol/L; 95% CI -0.81 to
-0.31; 7 trials, n = 624) [65-71], fish oils (WMD -0.81
mmol/L; 95% CI -1.11 to -0.50; 2 trials, n = 116) [80,81]],
alginic sodium diester (WMD -1.08 mmol/L; 95% CI -
1.38 to -0.78; 1 trial, n = 60) [84], and conjugated estro-
gens (WMD -0.87 mmol/L; 95% CI -1.20 to -0.54; 1 trial,
n = 44) in postmenopausal women[85]. More partici-
pants had 10% reduction of TC levels after treatment of
Xuezhikang against inositol nicotinate (16/18 vs. 7/17; RR
2.16; 95% CI 1.20 to 3.90) [72]. Xuezhikang was better
than fish oils in terms of more participants with 10%
reduction of TC levels (WMD 1.36; 95% CI 1.14 to 1.63;
2 trials, n = 146) [82,83]. No significant difference was
found between Xuezhikang and fenofibrate or gemfibrozil,
Xuezhikang and elastase or biphenalbid in lowering TC
levels. However, Zhibituo was less effective than fenofi-
brate (WMD 0.31 mmol/L; 95% CI 0.04 to 0.59; 2 trials,
n = 248) [32,104], but more effective than inositol nicoti-
Table 1: Composition and treatment regimens of red yeast rice preparations
Preparation Composition Dosage Administration
Red yeast rice dietary supplement 
(Cholestin) capsules
Extracts of fermented Monascus purpureus rice 2.4 g/day (containing 5 mg lovastatin) 0.6 g/cap 2 caps, twice daily
Xuezhikang capsule Extracts from fermented Monascus purpureus rice, 
Fructus Crataegi, Radix Salviae miltiorrhizae, Rhizoma 
Curcumae longae, Radix Rhizoma rhei, etc.
1.2 g/day (containing 10 mg lovastatin) 0.3 g/cap 2 caps, twice daily
Zhibituo tablet Extracts from fermented Monascus purpureus rice, 
Fructus Crataegi, Rhizoma Atractylodis 
macrocephalae, Rhizoma Alismatis orientalis, etc.
3.15 g/day (containing lovastatin 9 mg) 0.35 g/tab 3 tabs, thrice dailyChinese Medicine 2006, 1:4 http://www.cmjournal.org/content/1/1/4
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Table 2: Net benefit of RYR preparations in lipid profile in placebo-controlled trials
No. of subjects Baseline Post-treatment Difference P value
Mean (SD) Mean (SD) Mean (95% CI) % Change
TC levels (mmol/L)
Cholestin 42 6.47 (0.78) 5.43 (0.80) -1.04 (-1.38 to -0.70) -16% < 0.00001
Placebo 41 6.59 (0.75) 6.47 (0.93) -0.12 (-0.49 to 0.25) -2% 0.52
30 6.68 (0.98) 5.31 (0.84) -1.37 (-1.83 to -0.91) -21%
33 5.81 (0.63) 4.26 (0.63) -1.55 (-1.85 to -1.25) -27%
Xuezhikang 101 7.30 (1.40) 5.90 (1.40) -1.40 (-1.79 to -1.01) -19%
30 5.65 (1.31) 3.16 (1.31) -2.49 (-3.15 to -1.83) -44%
Subtotal: 194 -1.63 (-2.00 to -1.26) < 0.00001
28 6.72 (0.97) 6.43 (0.93) -0.29 (-0.79 to 0.21) -4%
30 5.84 (0.67) 4.94 (0.67) -0.90 (-1.24 to -0.56) -15%
Placebo 51 6.80 (1.40) 6.70 (1.40) -0.10 (-0.64 to 0.44) -1%
20 5.55 (1.02) 4.95 (1.02) -0.60 (-1.23 to 0.03) -11%
Subtotal: 129 -0.50 (-0.90 to -0.11) 0.01
9 5.90 (0.95) 4.94 (0.65) -0.96 (-1.71 to -0.21) -16%
Zhibituo 30 6.70 (1.10) 5.80 (0.90) -0.90 (-1.41 to -0.39) -13%
104 7.10 (1.70) 5.60 (1.30) -1.50 (-1.91 to -1.09) -21%
Subtotal: 143 -1.17 (-1.59 to -0.74) < 0.00001
9 5.83 (0.57) 5.56 (0.53) -0.27 (-0.78 to 0.24) -5%
Placebo 30 6.70 (1.50) 6.40 (1.30) -0.30 (-1.01 to 0.41) -4%
101 6.00 (1.80) 6.50 (0.70) 0.50 (0.12 to 0.88) 8%
Subtotal: 140 0.02 (-0.56 to 0.60) 0.95
TG levels (mmol/L)
Cholestin 42 1.50 (0.54) 1.40 (0.50) -0.10 (-0.32 to 0.12) -7% 0.38
Placebo 41 1.61 (0.52) 1.65 (0.53) 0.04 (-0.19 to 0.27) 2%
30 2.84 (0.57) 2.38 (0.62) -0.46 (-0.76 to -0.16) -16%
33 2.10 (0.92) 1.82 (0.92) -0.28 (-0.72 to 0.16) -13%
Xuezhikang 101 3.60 (2.40) 2.30 (1.60) -1.30 (-1.86 to -0.74) -36%
30 2.62 (0.58) 1.47 (0.58) -1.15 (-1.44 to -0.86) -44%
Subtotal: 194 -0.78 (-1.26 to -0.31) 0.001
28 2.74 (0.73) 2.57 (0.69) -0.17 (-0.54 to 0.20) -6%
Placebo 30 2.14 (0.94) 1.91 (0.94) 3.00 (1.60) -0.23 (-0.71 to 0.25) -0.30 (-0.92 to 0.32) -11%
51 3.30 (1.60) 3.00 (1.60) -0.30 (-0.92 to 0.32) -9%
20 2.50 (0.50) 2.11 (0.50) -0.39 (-0.70 to -0.08) -16%
Subtotal: 129 -0.29 (-0.49 to -0.09) 0.005
13 2.46 (1.23) 1.79 (0.57) -0.67 (-1.41 to 0.07) -27%
Zhibituo 30 3.40 (0.90) 2.10 (1.10) -1.30 (-1.81 to -0.79) -38%
104 3.40 (1.50) 2.30 (1.30) -1.10 (-1.48 to -0.72) -32%
Subtotal: 147 -1.10 (-1.38 to -0.82) < 0.00001
9 2.56 (0.88) 2.36 (0.64) -0.20 (-0.91 to 0.51) -8%
30 3.40 (1.10) 3.10 (1.20) -0.30 (-0.88 to 0.28) -9%Chinese Medicine 2006, 1:4 http://www.cmjournal.org/content/1/1/4
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Placebo 101 3.10 (0.40) 2.50 (1.40) -0.60 (-0.88 to -0.32) -19%
Subtotal: 140 -0.50 (-0.74 to -0.26) < 0.0001
LDL-C levels (mmol/L)
Cholestin 42 4.47 (0.70) 3.49 (0.70) -0.98 (-1.28 to -0.68) -22% < 0.00001
Placebo 41 4.65 (0.78) 4.53 (0.85) -0.12 (-0.47 to 0.23) -3% 0.51
30 3.94 (0.82) 2.83 (0.88) -1.11 (-1.54 to -0.68) -28%
33 4.13 (0.52) 2.80 (0.52) -1.33 (-1.58 to -1.08) -32%
Xuezhikang 101 4.80 (1.60) 3.50 (1.40) -1.30 (-1.71 to -0.89) -27%
30 3.00 (1.03) 2.10 (1.03) -0.90 (-1.42 to -0.38) -30%
Subtotal: 194 -1.23 (-1.41 to -1.05) <0.00001
28 4.13 (0.94) 4.01 (0.86) -0.12 (-0.59 to 0.35) -3%
30 4.24 (0.53) 3.41 (0.53) -0.83 (-1.10 to -0.56) -20%
Placebo 51 4.20 (1.60) 4.30 (1.60) 0.10 (-0.52 to 0.72) 2%
20 3.19 (0.87) 2.70 (0.87) -0.49 (-1.03 to 0.05) -15%
Subtotal: 129 -0.38 (-0.83 to 0.07) 0.10
Zhibituo 104 3.70 (1.60) 3.50 (1.40) -0.20 (-0.61 to 0.21) -5% 0.34
Placebo 101 3.70 (1.20) 3.70 (1.00) 0.00 (-0.30 to 0.30) 0% 1.00
HDL-C levels (mmol/L)
Cholestin 42 1.29 (0.34) 1.29 (0.36) 0.00 (-0.15 to 0.15) 0% 1.00
Placebo 41 1.19 (0.26) 1.19 (0.28) 0.00 (-0.12 to 0.12) 0% 1.00
30 1.50 (0.46) 1.67 (0.54) 0.17 (-0.08 to 0.42) 11%
33 1.37 (0.21) 1.16 (0.21) -0.21 (-0.31 to -0.11) -15%
Xuezhikang 101 1.20 (0.40) 1.40 (0.30) 0.20 (0.10 to 0.30) 17%
30 1.20 (0.21) 1.22 (0.21) 0.02 (-0.09 to 0.13) 2%
Subtotal: 194 0.04 (-0.17 to 0.24) 0.73
28 1.57 (0.69) 1.53 (0.32) -0.04 (-0.32 to 0.24) -3%
30 1.36 (0.24) 1.13 (0.24) -0.23 (-0.35 to -0.11) -17%
51 1.30 (0.40) 1.30 (0.30) 0.00 (-0.14 to 0.14) 0%
Placebo 20 1.22 (0.25) 1.00 (0.25) -0.22 (-0.37 to -0.07) -18%
Subtotal: 129 -0.13 (-0.26 to -0.01) 0.04
13 0.89 (0.41) 1.09 (0.41) 0.20 (-0.12 to 0.52) 22%
30 1.08 (0.11) 1.31 (0.17) 0.23 (0.16 to 0.30) 21%
Zhibituo 104 0.85 (0.14) 0.98 (0.26) 0.13 (0.07 to 0.19) 15%
Subtotal: 147 0.18 (0.10 to 0.26) < 0.0001
13 0.92 (0.19) 0.90 (0.17) -0.02 (-0.16 to 0.12) -2%
30 0.99 (0.20) 1.02 (0.28) 0.03 (-0.09 to 0.15) 3%
Placebo 101 0.89 (0.13) 0.80 (0.30) -0.09 (-0.15 to -0.03) -10%
Subtotal: 144 -0.04 (-0.12 to 0.03) 0.26
Table 2: Net benefit of RYR preparations in lipid profile in placebo-controlled trials (Continued)Chinese Medicine 2006, 1:4 http://www.cmjournal.org/content/1/1/4
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nate (WMD -0.73 mmol/L; 95% CI -1.13 to -0.33; 8 trials,
n = 608) [88-95], and fish oils (WMD -0.76 mmol/L; 95%
CI -1.04 to -0.49; 6 trials, n = 491) [97-102] by random
effect model due to significant heterogeneity (Table 3).
More participants treated by Zhibituo had 10% reduction
of TC levels compared with those treated by inositol nico-
tinate (23/30 vs. 13/30; RR 1.77; 95% CI 1.12 to 2.79)
[96] or those treated by fish oils (18/25 vs. 7/25; RR 2.57;
95% CI 1.31 to 5.05) [103]. Zhibituo appeared superior to
alginic sodium diester for the number of participants with
10% reduction of TC levels (105/121 vs. 67/89; RR 1.15;
95% CI 1.00 to 1.32) [105].
Xuezhikang did not differ from Zhibituo in TC-lowering
effect (WMD -0.03 mmol/L; 95% CI -0.25 to 0.20; 7 trials,
n = 701) [32,106-111] (Table 3).
Triglycerides (TG) levels (Tables 2 and 4)
There was a 13%–44% reduction of TG levels after treat-
ment by Xuezhikang, 27%–38% by Zhibituo, and 7% by
Cholestin. Compared with no treatment, Zhibituo showed
a significant effect on reducing TG levels (WMD -0.54
mmol/L; 95% CI -0.77 to -0.32; 2 trials, n = 112) [22,23].
Compared with placebo, all three RYR preparations signif-
icantly reduced TG levels (Cholestin: WMD -0.25 mmol/
L; 95% CI -0.47 to -0.03; 1 trial, n = 83 [7]; Xuezhikang:
WMD -0.40 mmol/L; 95% CI -0.70 to -0.10; 4 trials, n =
323 [8,24-26]; and Zhibituo: WMD -0.55 mmol/L; 95% CI
-0.99 to -0.10; 3 trials, n = 283) [27-29] (Table 4). Differ-
ent treatment duration showed similar effect of RYR prep-
arations in reducing TG levels compared with placebo by
4 weeks (WMD -0.32 mmol/L; 95% CI -0.58 to -0.07; 2
trials, n = 113) [25,26], 6 weeks (WMD -0.74; 95% CI -
1.10 to -0.37; 2 trials, n = 86) [27,28], 8 weeks (WMD -
0.35; 95% CI -0.5 to -0.21; 5 trials, n = 406) [7,8,24-26],
and 12 weeks (WMD -0.25; 95% CI -0.47 to -0.03; 1 trial,
n = 83) [7].
There was no statistically significant difference in TG lev-
els after treatment between Xuezhikang  or Zhibituo  and
simvastatin, pravastatin, lovastatin, atorvastatin, or fluv-
astatin. One trial presented data as number of subjects
with at least 20% reduction of TG levels, and it showed no
difference between Xuezhikang and lovastatin (47/60 vs.
59/77; RR 1.02; 95% CI 0.85 to 1.23) [64].
Compared with non-statin lipid lowering agents, there
was no significant difference between Xuezhikang  and
Table 3: Post-treatment total cholesterol levels (mmol/L) in randomized controlled trials
Interventions No. of trials [references] No. of participants Weighted mean difference 
(95% confidence interval)
P value
RYR vs. no intervention/placebo
Zhibituo vs. no intervention 2 [22, 23] 112 -1.27 (-1.50 to -1.05) < 0.00001
RYR supplement vs. placebo 1 [7] 83 -1.04 (-1.41 to -0.67) < 0.00001
Xuezhikang vs. placebo 4 [8, 24–26] 323 -1.04 (-1.46 to -0.62)* < 0.00001
Zhibituo vs. placebo 3 [27–29] 283 -0.80 (-1.03 to -0.57) < 0.00001
RYR vs. statins
Xuezhikang vs. simvastatin 15 [6, 30–43] 1455 0.05 (-0.27 to 0.37)* 0.76
Xuezhikang vs. pravastatin 7 [44–50] 594 - 0.20 (- 0.47 to 0.06)* 0.14
Xuezhikang vs. lovastatin 3 [51–53] 174 -0.05 (-0.27 to 0.18) 0.69
Xuezhikang vs. atorvastatin 1 [54] 60 -0.16 (-0.58 to 0.26) 0.46
Xuezhikang vs. fluvastatin 1 [55] 118 0.48 (0.24 to 0.72) 0.0001
Zhibituo vs. simvastatin 9 [32, 56–63] 728 0.11 (-0.03 to 0.25) 0.14
Zhibituo vs. provastatin 1 [22] 62 0.05 (-0.20 to 0.30) 0.70
Zhibituo vs. lovastatin 1 [57] 45 -0.11 (-0.48 to 0.26) 0.56
RYR vs. non-statin drugs
Xuezhikang vs. inositol nicotinate 7 [65–71] 624 -0.56 (-0.81 to -0.31)* < 0.0001
Xuezhikang vs. fenofibrate 5 [32, 73–76] 337 -0.13 (-0.46 to 0.20)* 0.44
Xuezhikang vs. gemfibrozil 3 [77–79] 156 -0.43 (-1.52 to 0.65)* 0.43
Xuezhikang vs. fish oils 2 [80, 81] 116 -0.81 (-1.11 to -0.50) < 0.00001
Xuezhikang vs. alginic sodium diester 1 [84] 60 -1.08 (-1.38 to -0.78) < 0.00001
Xuezhikang vs. conjugated estrogens 1 [85] 44 -0.87 (-1.20 to -0.54) < 0.00001
Xuezhikang vs. elastase 1 [86] 107 -0.10 (-0.49 to 0.29) 0.61
Xuezhikang vs. biphenalbid 1 [87] 64 0.12 (-0.31 to 0.55) 0.59
Zhibituo vs. inositol nicotinate 8 [88–95] 608 -0.73 (-1.13 to -0.33)* 0.0004
Zhibituo vs. fish oils 6 [97–102] 491 -0.76 (-1.04 to -0.49)* < 0.00001
Zhibituo vs. fenofibrate 2 [32, 104] 248 0.31 (0.04 to 0.59) 0.02
RYR versus RYR
Xuezhikang vs. Zhibituo 7 [32, 106–111] 701 -0.03 (-0.25 to 0.20)* 0.82
* Random effects modelChinese Medicine 2006, 1:4 http://www.cmjournal.org/content/1/1/4
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inositol nicotinate, fenofibrate, alginic sodium diester, or
elastase for TG levels. There was no difference between
Xuezhikang and inositol nicotinate in number of partici-
pants with over 20% reduction of TG levels (11/16 vs. 10/
16; RR 1.10; 95% CI 0.67 to 1.82) [72], and between
Xuezhikang and fish oils (58/78 vs. 44/70; RR 1.15; 95%
CI 0.8 to 1.64) [82,83]. However, Xuezhikang  was less
effective than gemfibrozil (WMD 0.41 mmol/L; 95% CI
0.30 to 0.51; 3 trials, n = 160) [77-79], but better than fish
oils (WMD -0.71 mmol/L; 95% CI -0.97 to -0.44; 2 trials,
n = 112) [80,81], conjugated estrogens (WMD -0.82
mmol/L; 95% CI -1.31 to -0.33; 1 trial, n = 44) [85] in
postmenopausal women, and biphenalbid (WMD -0.43
mmol/L; 95% CI -0.81 to -0.05; 1 trial, n = 64) [87]. Zhi-
bituo  showed a significant better TG-lowering effect
(WMD -0.39 mmol/L; 95% CI -0.62 to -0.16; 7 trials, n =
598) [88-93,95] compared with inositol nicotinate. How-
ever, there was no significant difference between Zhibituo
and inositol nicotinate in the number of participants with
over 20% reduction of TG levels (9/30 vs. 4/30) in one
trial [96]. Zhibituo did not differ from fish oils (WMD -
0.12 mmol/L; 95% CI -0.29 to 0.05; 5 trials, n = 394) [97-
100,102] or fenofibrate (WMD 0.33 mmol/L; 95% CI -
0.12 to 0.78; 2 trials, n = 248) [32,104] (Table 4). In a
small trial more participants appeared to have a 20%
reduction of TG levels by Zhibituo than by fish oils (20/23
vs. 9/19; RR 1.84; 95% CI 1.11 to 3.03) [103]. There was
a marginal effect of Zhibituo  compared with alginic
sodium diester for the number of participants with over
20% reduction of TG levels (69/121 vs. 38/89; RR 1.34;
95% CI 1.00 to 1.78) [105].
There was no significant difference between Xuezhikang
and Zhibituo in reducing TG levels (WMD 0.05 mmol/L;
95% CI -0.17 to 0.27; 7 trials, n = 727) (Table 4).
Low density lipoprotein cholesterol (LDL-C) levels (Tables 
2 and 5)
There was a 22% reduction of LDL-C levels by Cholestin
and 27%–32% by Xuezhikang, but 5% by Zhibituo. Zhi-
bituo appeared to have no effect on reducing LDL-C levels
compared with no treatment [22] or placebo [28]. The rel-
ative benefit of reducing LDL-C levels by Cholestin
against placebo was WMD -1.04 mmol/L (95% CI -1.38 to
-0.70; 1 trial, n = 83) [7], and by Xuezhikang against pla-
cebo (WMD) -0.74 mmol/L; 95% CI -0.93 to -0.55; 4 tri-
als, n = 323) [8,23-25] (Table 5). Different treatment
duration showed similar effect of RYR preparations in
reducing LDL-C levels compared with placebo by 4 weeks
(WMD -0.77 mmol/L; 95% CI -1.0 to -0.54; 2 trials, n =
Total cholesterol levels during the treatment in 8 randomized placebo-controlled trials Figure 1
Total cholesterol levels during the treatment in 8 randomized placebo-controlled trials.
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113) [25,26], 8 weeks (WMD -0.87; 95% CI -1.15 to -0.60;
5 trials, n = 406) [7,8,24-26], and 12 weeks (WMD -1.04;
95% CI -1.38 to -0.70; 1 trial, n = 83) [7].
Xuezhikang did not differ from simvastatin, pravastatin,
lovastatin, atorvastatin or fluvastatin for post-treatment
LDL-C levels. Zhibituo appeared to have the same effect as
pravastatin or lovastatin, but was less effective than simv-
astatin (WMD 0.22 mmol/L; 95% CI 0.04 to 0.39; 8 trials,
n = 601) [32,56-62]. Compared with non-statin lipid-low-
ering agents, Xuezhikang was similar to fenofibrate, conju-
gated estrogens or biphenalbid, but significantly better in
reducing LDL-C levels than inositol nicotinate (WMD -
0.63 mmol/L; 95% CI -0.96 to -0.30; 4 trials, n = 299) [66-
68,70], gemfibrozil (WMD -0.34 mmol/L; 95% CI -0.58
to -0.10; 3 trials, n = 152) [77-79], and fish oils (WMD -
0.89 mmol/L; 95% CI -1.41 to -0.37, 1 trial, n = 95) [81].
Zhibituo was better than fish oils in reducing LDL-C levels
(WMD -0.57 mmol/L; 95% CI -0.70 to -0.45; 5 trials, n =
489) [97-101], but less effective than fenofibrate (WMD
0.31 mmol/L; 95% CI 0.04 to 0.58; 1 trial, n = 90) [32]
(Table 5).
No significant difference was found between Xuezhikang
and Zhibituo in LDL-C levels (-0.08 mmol/L;-0.18 to 0.02;
5 trials, n = 628) [32,106,108,109,111] (Table 5).
High density lipoprotein cholesterol (HDL-C) levels 
(Tables 2 and 6)
There was an increase of HDL-C levels between 15% and
22% by Zhibituo. However, the findings for Xuezhikang
were not consistent ranging from a 2% to 17% increase
and 15% decrease in four trials. Cholestin did not change
the HDL-C levels after the treatment [7]. A beneficial effect
Table 4: Post-treatment triglycerides levels (mmol/L) in randomized controlled trials
Interventions No. of trials 
[references]
No. of participants Weighted mean 
difference (95% 
confidence interval)
P value
RYR vs. no 
intervention/placebo
Zhibituo vs. no intervention 2 [22, 23] 112 -0.54 (-0.77 to -0.32) < 0.00001
RYR supplement vs. 
placebo
1 [7] 83 -0.25 (-0.47 to -0.03) 0.03
Xuezhikang vs. placebo 4 [8, 24–26] 323 -0.40 (-0.70 to -0.10)* 0.008
Zhibituo vs. placebo 3 [27–29] 291 -0.55 (-0.99 to -0.10) 0.02
RYR vs. statins
Xuezhikang vs. simvastatin 14 [6, 30–42] 1251 -0.08 (-0.25 to 0.10)* 0.39
Xuezhikang vs. pravastatin 7 [44–50] 592 0.04 (- 0.29 to 0.38)* 0.79
Xuezhikang vs. lovastatin 3 [51–53] 168 -0.07 (-0.16 to 0.01) 0.09
Xuezhikang vs. atorvastatin 1 [54] 60 -0.02 (-0.16 to 0.12) 0.78
Xuezhikang vs. fluvastatin 1 [55] 118 0.09 (-0.1 4 to 0.32) 0.44
Zhibituo vs. simvastatin 9 [32, 56–63] 732 0.05 (-0.17 to 0.26)* 0.67
Zhibituo vs. provastatin 1 [22] 62 -0.02 (-0.19 to 0.15) 0.81
Zhibituo vs. lovastatin 1 [57] 45 -0.21 (- 0.61 to 0.19) 0.30
RYR vs. non-statin 
drugs
Xuezhikang vs. inositol 
nicotinate
7 [65–71] 636 -0.06 (-0.20 to 0.08) 0.38
Xuezhikang vs. fenofibrate 5 [32, 73–76] 337 0.42 (-0.17 to 1.01)* 0.16
Xuezhikang vs. gemfibrozil 3 [77–79] 160 0.41 (0.30 to 0.51) < 0.00001
Xuezhikang vs. fish oils 2 [80, 81] 112 -0.71 (-0.97 to -0.44) < 0.00001
Xuezhikang vs. alginic 
sodium diester
1 [84] 60 0.04 (-0.21 to 0.29) 0.75
Xuezhikang vs.conjugated 
estrogens
1 [85] 44 -0.82 (-1.31 to -0.33) 0.001
Xuezhikang vs. elastase 1 [86] 107 0.00 (-0.31 to 0.31) 1.00
Xuezhikang vs. biphenalbid 1 [87] 64 -0.43 (-0.8 1 to -0.05) 0.03
Zhibituo vs. inositol 
nicotinate
7 [88–93, 95] 598 -0.39 (-0.62 to -0.16)* 0.0008
Zhibituo vs. fish oils 5 [97–100, 102] 394 -0.12 (-0.29 to 0.05) 0.17
Zhibituo vs. fenofibrate 2 [32, 104] 248 0.33 (-0.12 to 0.78) 0.15
RYR vs. RTR
Xuezhikang vs. Zhibituo 7 [32, 106–111] 727 0.05 (-0.17 to 0.27)* 0.66
* Random effects modelChinese Medicine 2006, 1:4 http://www.cmjournal.org/content/1/1/4
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of increasing HDL-C levels was shown when Xuezhikang
was compared with placebo (WMD 0.11 mmol/L; 95%CI
0.05 to 0.17; 4 trials, n = 323) [8,24-26], and when Zhi-
bituo  was compared with no treatment (WMD 0.21
mmol/L; 95% CI 0.04 to 0.38; 1 trial, n = 62) [22] and
with placebo (WMD 0.21 mmol/L; 95% CI 0.15 to 0.27;
3 trials, n = 291) [27-29] (Table 6). Different treatment
durations showed that of RYR preparations increased
HDL-C levels compared with placebo by 6 weeks (WMD
0.27; 95% CI 0.17 to 0.38; 2 trials, n = 86) [27,28] and 8
weeks (WMD 0.11; 95% CI 0.05 to 0.16; 5 trials, n = 406)
[7,8,24-26]. There was no significant difference between
RYR and placebo at 4 weeks and at 12 weeks for HDL-C
levels [7,25,26].
Compared with statins, Xuezhikang appeared better than
lovastatin in raising HDL-C levels (WMD 0.06 mmol/L;
95% CI 0.00 to 0.11; 3 trials, n = 152) [51,53]. Zhibituo
was inferior to simvastatin (WMD -0.07 mmol/L; 95% CI
-0.12 to -0.03; 9 trials, n = 666) [32,56-63]. There was no
significant difference among other comparisons of RYR
preparations and statins. Compared with non-statins,
Xuezhikang was superior to inositol nicotinate (WMD 0.17
mmol/L; 95% CI 0.06 to 0.28; 7 trials, n = 608) by ran-
dom effects model [65-71], fish oils (WMD 0.17 mmol/L;
95% CI 0.09 to 0.25; 2 trials, n = 70) [80,81], alginic
sodium diester (WMD 0.86 mmol/L; 95% CI 0.75 to 0.97;
1 trial, n = 60) [84], elastase (WMD 0.20 mmol/L; 95% CI
0.10 to 0.30; 1 trial, n = 107) [86], and to biphenalbid
(WMD 0.25 mmol/L; 95% CI 0.11 to 0.39; 1 trial, n = 64)
[87]. There was no significant difference between
Xuezhikang and fenofibrate, gemfibrozil, or estrogens in
affecting HDL-C levels. Zhibituo was superior to inositol
nicotinate (WMD 0.18 mmol/L; 95% CI 0.09 to 0.27; 6
trials, n = 422) [89-91,93-95] and to fish oils (WMD 0.14
mmol/L; 95% CI 0.06 to 0.23; 6 trials, n = 400) [97-102]
both in random effects model. There was no significant
difference between Zhibituo and fenofibrate (WMD -0.13
mmol/L; 95% CI -0.37 to 0.11; 2 trials, n = 248) [32,104].
No significant difference was found between Xuezhikang
and Zhibituo in affecting HDL-C levels (WMD 0.04 mmol/
L; 95% CI -0.02 to 0.11; 7 trials, n = 627) [32,106-111]
(Table 6).
Adverse effects
Seventy-seven trials reported outcomes of adverse effects,
and the incidence rate ranged from 1.3% to 36%. The
most commonly reported adverse effects were dizziness,
low appetite, nausea, stomach-ache, abdominal disten-
Table 5: Post-treatment low-density lipoprotein cholesterol levels (mmol/L) in randomized controlled trials
Interventions No. of trials [references] No. of participants Weighted mean difference 
(95% confidence interval)
P value
RYR vs. no intervention/placebo
Zhibituo vs. no intervention 1 [22] 62 -0.16 (-0.71 to 0.39) 0.57
RYR supplement vs. placebo 1 [7] 83 -1.04 (-1.38 to -0.70) < 0.00001
Xuezhikang vs. placebo 4 [8, 24–26] 323 -0.74 (-0.93 to -0.55) < 0.00001
Zhibituo vs. placebo 1 [29] 205 -0.20 (-0.53 to 0.13) 0.24
RYR vs. statins
Xuezhikang vs. simvastatin 13 [6, 30–34, 36–38, 40–43] 1238 0.14 (-0.05 to 0.33)* 0.14
Xuezhikang vs. pravastatin 7 [44–50] 587 -0.09 (- 0.20 to 0.02)* 0.11
Xuezhikang vs. lovastatin 3 [51–53] 191 0.00 (- 0.26 to 0.27) 0.98
Xuezhikang vs. atorvastatin 1 [54] 60 0.20 (-0.10 to 0.50) 0.19
Xuezhikang vs. fluvastatin 1 [55] 118 0.14 (-0.10 to 0.38) 0.26
Zhibituo vs. simvastatin 8 [32, 56–62] 601 0.22 (0.04 to 0.39) 0.02
Zhibituo vs. provastatin 1 [22] 62 -0.11 (-0.60 to 0.38) 0.66
Zhibituo vs. lovastatin 1 [57] 45 0.03 (-0.30 to 0.36) 0.86
RYR vs. non-statin drugs
Xuezhikang vs. inositol nicotinate 4 [66–68, 70] 299 -0.63 (-0.96 to -0.30) 0.0002
Xuezhikang vs. fenofibrate 3 [32, 74, 76] 220 -0.10 (-1.05 to 0.85)* 0.84
Xuezhikang vs. gemfibrozil 3 [77–79] 152 -0.34 (-0.58 to -0.10) 0.005
Xuezhikang vs. fish oils 1 [81] 95 -0.89 (-1.41 to -0.37) 0.0008
Xuezhikang vs. conjugated estrogens 1 [85] 44 -0.10 (-0.43 to 0.23) 0.55
Xuezhikang vs. biphenalbid 1 [87] 64 -0.06 (-0.32 to 0.20) 0.65
Zhibituo vs. fish oils 5 [97–101] 489 -0.57 (-0.70 to -0.45) < 0.00001
Zhibituo vs. fenofibrate 1 [32] 90 0.3 1 (0.04 to 0.58) 0.02
RYR vs. RYR
Xuezhikang vs. Zhibituo 5 [32, 106, 108, 109, 111] 628 -0.08 (-0.18 to 0.02) 0.12
* Random effects modelChinese Medicine 2006, 1:4 http://www.cmjournal.org/content/1/1/4
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sion, and diarrhoea. A small proportion of participants
suffered from increased serum BUN and ALT levels. The
trials did not report serious adverse events.
Cost-effectiveness
One trial evaluated cost-effectiveness of Xuezhikang  vs.
pravastatin for treatment of hypercholesterolemia [49].
For a reduction of 1 mmol/L TC level, the cost of
Xuezhikang  and pravastatin was 57 USD and 78 USD
respectively. For a reduction of 1 mmol/L TG level, the
cost of Xuezhikang and pravastatin was 242 USD and 820
USD respectively; and for a reduction of 1 mmol/L LDL-C
level, the cost was 59 USD and 84 USD respectively.
Discussion
Based on this review and meta-analysis, three different
kinds of RYR preparations tested by in randomized trials
demonstrate beneficial effects on reducing TC, TG, and
LDL-C levels, and on increasing HDL-C levels in individ-
uals with hyperlipidemia. The treatment duration of RYR
ranged from 4 to 24 weeks (median of 8 weeks), and the
lipid modification effects have been shown at four weeks
of the treatment, and the effects remained at 24 weeks of
the treatment. Long-term follow-up effects after the treat-
ment have not been reported by the trials. The use of RYR
preparations seems safe and well tolerated.
Before accepting the findings of this review to form a basis
for clinical practice, we need to consider the following
weaknesses in this review. First, the randomized trials in
this review had several methodological flaws in terms of
insufficient reporting of generation methods of the alloca-
tion sequence, allocation concealment, and double blind-
ing. The trials provided limited descriptions of study
Table 6: Post-treatment high-density lipoprotein cholesterol levels (mmol/L) in randomized controlled trials
Interventions No. of trials 
[references]
No. of participants Weighted mean 
difference its (95% 
confidence interval)
P value
RYR vs. no 
intervention/placebo
Zhibituo vs. no intervention 1 [22] 62 0.21 (0.04 to 0.38) 0.02
RYR supplement vs. 
placebo
1 [7] 83 0.10 (-0.04 to 0.24) 0.16
Xuezhikang vs. placebo 4 [8, 24–26] 323 0.11 (0.05 to 0.17) 0.0008
Zhibituo vs. placebo 3 [27–29] 291 0.21 (0.15 to 0.27) < 0.00001
RYR vs. statins
Xuezhikang vs. simvastatin 14 [6, 30–34, 36–43] 1277 0.06 (-0.11 to 0.22)* 0.49
Xuezhikang vs. pravastatin 7 [44–50] 587 -0.01 (-0.06 to 0.03) 0.51
Xuezhikang vs. lovastatin 3 [51–53] 152 0.06 (0.00 to 0.11) 0.05
Xuezhikang vs. atorvastatin 1 [54] 60 0.01 (-0.17 to 0.19) 0.91
Xuezhikang vs. fluvastatin 1 [55] 118 -0.02 (-0.1 0 to 0.06) 0.62
Zhibituo vs. simvastatin 9 [32, 56–63] 666 -0.07 (-0.12 to -0.03) 0.0009
Zhibituo vs. provastatin 1 [22] 62 -0.02 (-0.22 to 0.18) 0.85
Zhibituo vs. lovastatin 1 [57] 45 -0.07 (-0.23 to 0.09) 0.39
RYR vs. non-statin 
drugs
Xuezhikang vs. inositol 
nicotinate
7 [65–71] 608 0.17 (0.06 to 0.28)* 0.002
Xuezhikang vs. fenofibrate 4 [32, 73, 74, 76] 257 0.03 (-0.06 to 0.13) 0.49
Xuezhikang vs. gemfibrozil 2 [77, 79] 108 -0.03 (-0.3 5 to 0.28) 0.83
Xuezhikang vs. fish oils 2 [80, 81] 70 0.17 (0.09 to 0.25) < 0.0001
Xuezhikang vs. alginic 
sodium diester
1 [84] 60 0.86 (0.75 to 0.97) < 0.00001
Xuezhikang vs. conjugated 
estrogens
1 [85] 44 0.00 (-0.09 to 0.09) 1.00
Xuezhikang vs. elastase 1 [86] 107 0.20 (0.10 to 0.30) < 0.0001
Xuezhikang vs. biphenalbid 1 [87] 64 0.25 (0.11 to 0.39) 0.0003
Zhibituo vs. inositol 
nicotinate
6 [89–91, 93–95] 422 0.18 (0.09 to 0.27)* < 0.0001
Zhibituo vs. fish oils 6 [97–102] 400 0.14 (0.06 to 0.23)* 0.001
Zhibituo vs. fenofibrate 2 [32, 104] 248 -0.13 (-0.37 to 0.11) 0.28
RYR vs. RYR
Xuezhikang vs. Zhibituo 7 [32, 106–111] 627 0.04 (-0.02 to 0.11)* 0.20
* Random effects modelChinese Medicine 2006, 1:4 http://www.cmjournal.org/content/1/1/4
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design, and most trials stated only that patients were ran-
domly assigned; thus the information does not allow a
judgement of whether or not it was conducted properly.
We therefore state that the differences between RYR prep-
aration and control drugs may be associated with the
methodologically less rigorous trials [16-19]. The sample
size for trials comparing RYR with statins or other estab-
lished treatments was not justified and we do not know if
the trials were designed as 'equivalence trials'. The limited
number of trials with adequate quality prohibits us from
performing meaningful sensitivity analyses to illuminate
robustness of the results in the review.
Second, Vickers and colleagues [112] found that some
countries, including China, publish unusually high pro-
portions of positive results, for which publication bias is a
possible explanation. All identified studies for this sys-
tematic review originated from China except one trial con-
ducted in the USA and published in an international peer-
reviewed journal [7]. Inability to identify unpublished eli-
gible trials from the searching, trials with small samples
and positive findings may raise the issue of publication
bias.
There are some variations in RYR preparations and treat-
ment regimens including composition, dosage and dura-
tion. Cholestin is an extract from RYR containing a special
strain of yeast which produces monacolin K (lovastatin)
[7]. Xuezhikang and Zhibituo are two Chinese proprietary
medicines that contain other herbs in addition to RYR as
main components. In some trials, placebo effects are sub-
stantial compared with baseline as demonstrated in trials
of Xuezhikang where placebo treatment achieved 1% to
15% reduction of TC levels, and 6% to 16% reduction of
TG levels (Table 2). Therefore, in non-placebo-controlled
and non-double blind trials, placebo effects may add to
the complexity of interpreting the present findings of the
overall beneficial effects, and the interpretation should be
taken with caution.
Given the generally low methodological quality of the
randomized trials and potential publication bias, we sug-
gest further rigorously designed trials are still needed
before RYR preparation could be recommended for clini-
cal use or as an alternative treatment to statins. The cur-
rently ongoing placebo-controlled trials in Europe may
provide useful information [21]. In addition to anti-
hyperlipidemic effects of RYR preparations, cost-effective-
ness and safety should be further investigated in future tri-
als [113].
Conclusion
Current evidence from randomized trials shows short-
term beneficial effects of RYR preparations on lipid mod-
ification. More rigorous trials are needed, and long-term
effects and safety should be investigated if RYR prepara-
tions are to be recommended as one of the alternative
treatments for primary hyperlipidemia.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
JL conceived, designed, drafted the review, and performed
study selection, data extraction, analyses, and interpreta-
tion. JZ did the literature search, study selection, and
cross-checked the data extraction; YS developed the search
strategy, performed electronic searches and retrieved arti-
cles; SG, TA, and VF provided methodological perspec-
tives, and revised the review. All authors contributed to
the writing of the review.
Acknowledgements
We thank Dr Antonio Bianchi for providing information on ongoing study 
on RYR preparation 'Lipolysar', and Beijing Weixin for unpublished study 
on Xuezhikang, and Pharmalogica in Norway for 'Hypocol'.
References
1. Monascus purpureus (monograph).  Altern Med Rev 2004,
9(2):208-210.
2. Ma J, Li Y, Ye Q, Li J, Hua Y, Ju D, Zhang D, Cooper R, Chang M: Con-
stituents of red yeast rice, a traditional Chinese food and
medicine.  J Agric Food Chem 2000, 48(11):5220-5.
3. Patrick L, Uzick M: Cardiovascular disease: C-reactive protein
and the inflammatory disease paradigm: HMG-CoA reduct-
ase inhibitors, alpha-tocopherol, red yeast rice, and olive oil
polyphenols. A review of the literature.  Altern Med Rev 2001,
6(3):248-71.
4. Heber D, Lembertas A, Lu QY, Bowerman S, Go VL: An analysis of
nine proprietary Chinese red yeast rice dietary supplements:
implications of variability in chemical profile and contents.  J
Altern Complement Med 2001, 7(2):133-9.
5. Wang J, Lu Z, Chi J, Wang W, Su M, Kou W, Yu P, Yu L, Chen L, Zhu
JS, Chang J: Multicenter clinical trial of the serum lipid-lower-
ing effects of a Monascus purpureus (red yeast) rice prepara-
tion from traditional Chinese medicine.  Cur Ther Res 1997,
58:964-978.
6. Kou WR, Lu ZL, Guo JX, Li HY, Xue SW, Lin YZ, Wu XS, Chen H:
Effect of Xuezhikang on the treatment of primary hyperlipi-
demia.  Zhonghua Neike Zazhi 1997, 36(8):529-31.
7. Heber D, Yip I, Ashley JM, Elashoff DA, Elashoff RM, Go VL: Choles-
terol-lowering effects of a proprietary Chinese red-yeast-
rice dietary supplement.  Am J Chin Nutr 1999, 69(2):231-6.
8. Shen ZW, Yu PL, Sun MZ, Chi JM, Zhou YF, Zhu XS, Yang CY, He
CF: Prospective study of Xuezhikang for treatment of pri-
mary hyperlipidemia.  Natl Med J China 1996, 76(2):156-7.
9. Liu SS, Kou MK, Ding H, Li CM, He L, He L, Zhang CM, Li YF, Li ZF,
Yang MJ: The clinical observation of hyperlipoproteinemia
treated with Zhibituo.  Chengdu Zhongyiyao Daxue Xuebao 1996,
19(3):12-5.
10. Kreisberg RA, Oberman A: Medical management of hyperlipi-
demia/dyslipidemia.  J Clin Endocrinol Metab 2003, 88(6):2445-61.
11. Moghadasian MH: A safety look at currently available statins.
Expert Opin Drug Saf 2002, 1(3):269-74.
12. Alcocer L: Statins for everybody? New evidence on the effi-
cacy and safety of the inhibitors of HMG Co-A reductase.  Am
J Ther 2003, 10(6):423-8.
13. Bellosta S, Paoletti R, Corsini A: Safety of statins: focus on clinical
pharmacokinetics and drug interactions.  Circulation 2004,
109:11150-7.
14. Thompson Coon JS, Ernst E: Herbs for serum cholesterol reduc-
tion: a systematic review.  J Fam Pract 2003, 52(6):468-78.Chinese Medicine 2006, 1:4 http://www.cmjournal.org/content/1/1/4
Page 12 of 13
(page number not for citation purposes)
15. Expert Panel on Detection, Evaluation, and Treatment of High Blood
Cholesterol in Adults: Executive Summary of the Third Report
of the National Cholesterol Education Program (NCEP)
Expert Panel on Detection, Evaluation, and Treatment of
High Blood Cholesterol in Adults (Adult Treatment Panel
III).  JAMA 2001, 285(19):2486-97.
16. Schulz KF, Chalmers I, Hayes R, Altman D: Empirical evidence of
bias.  JAMA 1995, 273(5):408-12.
17. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, Tugwell P,
Klassen TP: Does quality of reports of randomized trials affect
estimates of intervention efficacy reported in meta-analyses.
Lancet 1998, 352(9128):609-13.
18. Kjaergard LL, Villumsen J, Gluud C: Reported methodological
quality and discrepancies between large and small rand-
omized trials in meta-analyses.  Ann Intern Med 2001,
135(11):982-9.
19. Clarke M, Oxman AD: Assessment of study quality. Cochrane
Reviewers' Handbook 4.2.0 [updated March 2003].  In The
Cochrane Library Issue 2 Oxford: Update Software; 2003. 
20. Higgins JPT, Thompson SG, Deeks JJ, Altman DG: Measuring incon-
sistency in meta-analyses.  BMJ 2003, 327(7414):557-60.
21. Personal communication with the trial sponsors in Norway
and Italy.  .
22. Tang HL: Randomized controlled study of Diao Zhibituo for
lipid modulation effect.  Sichuan Yixue 2004, 25(1):78-9.
23. Zhao YL, Ouyang HB: Observation on therapeutic effects of
Zhibituo  for treatment of hyperlipidemia.  Changchun Yixue
Zazhi 1998, 11(1):21.
24. Cheng XM, Yu ZM, Luo HD, Qiu YH, Chen MX: Effect of
Xuezhikang on endothelial function in patients with hyperlip-
idemia.  Chin J Arterioscler 2001, 9(3):235-7.
25. Qin SC, Zhang WQ, Qi P, Zhao ML, Dong ZN, Li YC, Xu XM, Fang
X, Fu L: Randomized, double blind, controlled trial for the
clinical therapeutic effects of Xuezhikang in the elderly with
hyperlipidemia.  Zhonghua Neike Zazhi 1998, 37(6):401-2.
26. Xiao M, Ye P: Clinical observation of Xuezhikang for treatment
of hyperlipidemia.  Shuli Yixue Zazhi 2001, 14(3):244-5.
27. Huang GZ, Yang S, Wu ZG: Observation on therapuetic effect
of Zhibituo for treatment of hyperlipidemia.  Dier Junyi Daxue
Xuebao 1998, 19(1):94-5.
28. Peng DY: Observation on the effect of Zhibituo in treating
hyperlipidemia.  Zhongguo Yejin Gongye Yixue Zazhi 1998,
15(4):201-3.
29. Xu JM, Chen SX, Hu WY, Cai NS, Xu Q, Wu ZG, Sun KX: Zhibituo
vs. placebo treatment of hyperlipidemia a double blind ran-
domized and multicenter study.  Zhongguo Xinyao Yu Linchuang
Zazhi 1997, 16(1):47-51.
30. Chen FJ, Ruan Q, Qi HW, Yuan PY: Clinical observation of
Xuezhikang in treating middle and old age hyperlipidemia.
Shanghai Yufangyixue Zazhi 2003, 15(5):222-3.
31. Chen LL, Liu J: Effects of Xuezhikang on hypercholesterolemia.
Yiyao Daobao 2002, 21(1):31-2.
32. Li QL, Zhang YF: Clinical observation on effect of Taizhi'an cap-
sule in treating 150 patients with hyperlipidemia.  Zhongguo
Zhongxiyi Jiehe Zazhi 2003, 23(5):335-7.
33. Lu GP, Huo SQ, Shen YC, Gong LS: Comparison of the effects of
Xuezhikang with simvastatin on lipid profile modification in
patients with hypercholesterolemia.  Zhonghua Neike Zazhi
1998, 37(6):371-3.
34. Quan SL, Wang W, Qu XW, Chen J: Controlled observation on
therapeutic effects of Xuezhikang and simvastatin for treat-
ment of hypercholesterolemia.  Zhonghua Shiyong Yixue 2003,
3(5):427.
35. Shen G, Wang J, Wang JF: Comparison of the effects of the
herbal lipid regulator decoction, Xuezhikang and simvastatin
on lipid modulation in the middle-aged and elderly subjects
with hyperlipidemia.  Zhongguo Jiceng Yiyao 2000, 7(4):280-1.
36. Wang SH, Sun JL, Liu HQ: Therapeutic observations of
Xuezhikang for treatment of 60 cases of elderly with hyperli-
pidemia.  Anhui Linchuang Zhongyi Zazhi 2003, 15(6):474-5.
37. Wang XL, Hu XM: Comparison of Xuezhikang and simvastatin
in regulating lipids for hypercholesterolemia.  Zhongxiyi Jiehe
Xinnaoxueguanbing Zazhi 2004, 2(6):319-20.
38. Xi BL, Ren JY: Effects of Xuezhikang vs. simvastatin in treating
hyperlipidemia.  Guowai Yixue: Xin Xueguanbing Fence 2002,
29(4):233-4.
39. Zeng TK: Observation of the therapeutic effects of Xuezhikang
for treatment of 77 elderly with hyperlipidemia.  Shoudu Yiyao
1999, 6(11):49.
40. Zhang G, Zhang KX, Xu Z, Guang XF: Comparison of lipid-lower-
ing effects of Xuezhikang and Simvastatin for hyperlipidemia.
Shoudu Yiyao 1998, 5(6):35-6.
41. Zhao XH, Jiang XM, Ao LJ: Therapeutic observations of
Xuezhikang  for treatment of hyperlipidemia.  Yunnan Yiyao
1998, 19(1):26.
42. Zheng Y, Luo XZ, Wang SL, Yang YJ: Clinical controlled study on
the therapeutic effects of Xuezhikang and Simvastatin.  Zhong-
guo Yaoshi 2001, 36(10):715.
43. Zhu QF, Jiang L, Wang Y: Effects of Xuezhikang and simvastatin
on apolipoprotein B and A1 in patients with hyperlipidemia.
Guangming Zhongyi 2003, 18(5):24-5.
44. Chen L, Qin YW, Guo RB: Clinical efficacy of capsule
Xuezhikang  in treatment of hypercholesterolemia.  Yaoxue
Fuwu Yu Yanjiu 2002, 2(1):39-40.
45. Jin W, Yang H, Zhang C, Zhang CJ, Xu YH: Therapeutic observa-
tions of Xuezhikang for treatment of primary hyperlipidemia.
Zhongguo Zhongxiyi Jiehe Zazhi 1997, 17(7):434-5.
46. Lei HZ: Effects of Xuezhikang on endothelial function in aged
patients with hyperlipidemia.  Guangxi Yixue 2004, 26(4):495-7.
47. Li YS, Lei HZ, Zhu MJ: Clinical observations of 41 cases of eld-
erly with hyperlipidemia treated with Xuezhikang.  Zhongguo
Quanke Yixue 2003, 6(2):163.
48. Wang DG, Li D, Nie ZY: Application of cost-effectiveness anal-
ysis in Xuezhikang and pravastatin for the treatment hyperc-
holesterolemia.  Zhongguo Yaoshi 2003, 12(9):53-5.
49. Xu CB, Hu DY, Kang LP, Tian YW, Gao MM, Xu ZM, Jin SY, Ma FY,
Ma M, Shi XY, Zhang BH, Long NZ, Li L, Xue L, Zhang JH, Chen XL,
Dai CX: Comparative study of relatively long-term therapy
for dyslipidemia with low-dose Xuezhikang or pravastatin in
Chinese patients.  Zhongguo Yaoxue 2000, 9(4):218-22.
50. Yu CY, Zhang C, Yang H, Jin W: Observations of therapeutic
effects of Xuezhikang  for treatment of primary hyperlipi-
demia.  Heilongjiang Yixue Zazhi 2004, 17(2):151-2.
51. Li BH, Zheng GJ, Zhang WG, Xu M, Ren P: Clinical observations
of Ruanmaijianzhi capsule in the treatment of dyslipidemia.
Hebei Zhongyi Zazhi 2004, 26(9):657-9.
52. Xu SG: Analysis of therapeutic effect of Xuezhikang for treat-
ment of primary hypercholesterolemia.  Henon Yixue Xinxi
2002, 10(13):6-7.
53. Zheng FS, Long XD, Liu HM, Liu YL, Bao YZ, Yu M: Comparison of
lovastatin and Chinese Xuezhikang in lipid modification for
primary hyperlipidemia.  Yunan Yixue 2000, 21(5):442-3.
54. Shen MY: Comparison of the effects of Xuezhikang and atorv-
astatin for treatment of hyperlipidemia.  Zhonghua Shiyong Yiyao
Zazhi 2003, 2(5):439-40.
55. Wang AH, Zhang GD: Comparison of the therapeutic effects of
Xuezhikang  and Lescol for treatment of hyperlipidemia.
Zhongguo Zonghe Yixue 2002, 3(7):617-8.
56. Chen ZM: Comparison of the therapeutic effects of simvasta-
tin and Zhibituo for treatment of hyperlipidemia.  Guangxi Yike
Daxue Xuebao 2001, 18(4):543.
57. Guo WC, Feng WJ: Clinical observations of statin alone or
combined with unsaturated fatty acids for the treatment of
combined hyperlipidemia in elderly people.  Beijing Yixue 2003,
25(1):25-7.
58. Guo XM, Tu L, Mi S: Comparison of the therapeutic effects of
Zhibituo  and simvastatin for regulating dyslipidemia.
Zhongyao Yaoli Yu Linchuang 1999, 15(6):46-8.
59. Huang YL, Zhou JG, Zhang HF, Shi YX, Wang MS: Comparison of
the therapeutic effects of simvastatin and Zhibituo for the
elderly with hyperlipidemia.  Yixue Yu Gongcheng 2001, 3(1):24-7.
60. Yang WJ, Fu XJ: Comparison of the therapeutic effects of Zhi-
bituo  and simvastatin for treatment of hyperlipidemia.
Zhongguo Xiandai Yiyao Yu Jishu 2003, 3(2):2-4.
61. Zhang GR: Comparison of Zhibituo and simvastatin for their
effects on hyperlipidemia.  Guangxi Yixue 2002, 24(5):713-4.
62. Zhang QL: Comparative interventional therapies of dyslipi-
demia by simvastatin and Zhibituo with 60 cases.  Guoji Yiyao
Weisheng Daobao 2004, 10(10):29-30.
63. Zheng CJ, Wang P: Zhibituo vs. simvastatin in treatment of
hyperlipidemia.  Zhongguo Yaoshi 2001, 4(6):447-8.Chinese Medicine 2006, 1:4 http://www.cmjournal.org/content/1/1/4
Page 13 of 13
(page number not for citation purposes)
64. Wang SX: Comparison of the therapeutic effects of
Xuezhikang and lovastatin.  Xiandai Zhongxiyi Jiehe Zazhi 2004,
13(20):2707.
65. Li DX, Li YF, Lu HY: Comparison of the effects of Xuezhikang
with inositol hexanicotinate on lipid profile modification.
Henan Zhigong Yixueyuan Xuebao 2000, 12(1):17-8.
66. Li YM, Sun RX: Therapeutic observations on Xuezhikang for
treatment of hyperlipidemia.  Zhongguo Shiyong Xiangcun Yisheng
Zazhi 2004, 11(8):25-6.
67. Liu L, Li JP, Shen PN: Clinical observations of Xuezhikang for
treatment of mixed type of hyperlipidemia.  Zhonghua Shiyong
Yixue 2000, 16(12):1047-8.
68. Qi P, Huang Y, Deng J: Effects of Xuezhikang vs. Inositol niaci-
nate in treating hyperlipidemia.  Jiangxi Yixueyuan Xuebao 2002,
42(4):24-5.
69. Yang SS: Xuezhikang for treatment of 76 patients with hyperl-
ipidemia.  Zhongchengyao 2002, 24(10):815-6.
70. Zhang JS: Comparison of Xuezhikang and inositol nicotinate
for treatment of hyperlipidemia.  Zhiye Yu Jiankang 2002,
18(1):138-40.
71. Zheng JR, Wang B: Effects of Xuezhikang on treatment of pri-
mary hyperlipidemia.  Yixue Luntan Zazhi 2004, 25(14):21-2.
72. Zhou ZL, Liu CH: Xuezhikang for treatment of 20 cases of
hyperlipidemia.  Hunan Zhongyiyao Daobao 1999, 5(7):25.
73. Jiang HP: Comparison of the therapeutic effects and compli-
ance of Xuezhikang and Fenofibrate in patients with hyperli-
pidemia.  Xiandai Zhenduan Yu Zhiliao 2001, 12(Suppl):29.
74. Li GR, Li JP, Mai WY, Zeng Y: Micronised fenofibrate for treat-
ment of mixed type of hyperlipidemia.  Guangdong Yixue 1999,
20(11):895-6.
75. Ma F, Ma XH: Clinical observation of Finofibrate and
Xuezhikang for treatment of hyperlipidemia.  Zhongguo Hang-
tianye Yiyao 2003, 5(1):55-6.
76. Zhu WM, Wu SR: Effects and safety of combined treatment by
Xuezhikang  and micronized fenofibrate in patients with
hyperlipidemia.  Zhongguo Linchuang Yixue Zazhi 2003, 4(2):18-20.
77. Jiang JB, Hao XY, Deng CQ, Zhou HT, Lin J: Effects of Xuezhikang
on serum lipid profile, thromboxane A2 and prostacyclin in
patients with hyperlipidemia.  Zhonghua Neike Zazhi 1999,
38(8):517-9.
78. Wang CW, Gao FM, You L: Clinical study on the therapeutic
effects of Xuezhikang  for treatment of hyperlipidemia.
Mudanjiang Yixueyuan Xuebao 2000, 21(3):13.
79. Wang YF, Yang CK, Xu WJ, Sun L, Liu B, Wang GG: Xuezhikang,
gemfibrozil for regulation of hyperlipidemia in elderly and
insulin sensitivity.  Zhongguo Xinyao Zazhi 1998, 7(3):209-11.
80. Liu ZB: Xuezhikang for treatment of 40 cases of hyperlipi-
demia.  Linchuang Huicui 1998, 13(8):367-8.
81. Xia CH: Comparison of lipid modification of Xuezhikang and
Duoxikang in hyperlipidemia.  Suzhou Yixueyuan Xuebao 1999,
19(9):1015-6.
82. Xu WY, Yan YZ, Tang ZH: Therapeutic observations on
Xuezhikang capsules for treatment of hyperlipidemia.  Haixia
Yaoxue 2003, 15(2):65-6.
83. Zheng H, Dan XY, Ning H, Xue B: Observations of Xuezhikang on
clinical effects and haemorheology.  Hebei Yiyao 2001, 7(1):46-8.
84. Zhang WM, Yang JX, Li F, Zhang GW: Observations of Xuezhikang
in treatment of hyperlipidemia and abnormal haemorheol-
ogy.  Henan Shiyong Shenjingbing Zazhi 2000, 3(3):47-8.
85. Feng JC, Wang JS, Wang CP, Jiang YJ, Tan GZ: Effects of conju-
gated estrogen and Xuezhikang in low dosage on blood lipid
in postmenopausal women.  Xiandai Zhongxiyi jiehe Zazhi 2000,
9(23):2334-5.
86. Kong YM, Gao H, Liu XL: Clinical observations of the lipid-low-
ering effects of Xuezhikang and elastase.  Zhongguo Yaoshi 1999,
8(3):56.
87. Yan HD, Guo JH, Jia ST: Observations of the short-term effects
of Probucol in treatment of hyperlipidemia.  Shanxi Linchuang
Yixue 1999, 8(2):103-4.
88. Bi JZ, Ma SZ, Li YQ: Observations on the therapeutic effects of
Diao Zhibituo for treatment of hyperlipidemia.  Shiyong Zhongx-
iyi jiehe Zazhi 1996, 9(12):729.
89. Cai MX, Deng JX, Lu LF: Clinical observations on Diao Zhibituo
for treatment of hyperlipidemia.  Fujian Yiyao Zazhi 1997,
19(2):83-4.
90. Cong B: Observations on the therapeutic effects of Zhibituo
for treatment of hyperlipidemia.  Hebei Yiyao 1999, 5(3):60-1.
91. Huang LJ, Chen MS: Comparison of Diao Zhibituo and Inositol
nicotinate for the lipid lowering effects.  Zhongyuan Yikan 1997,
24(1):8-10.
92. Li FL, Zeng WH: Comparison of Zhibituo and Inositol nicoti-
nate for treatment of hyperlipidemia.  Nongken Yixue 2002,
24(3):198-9.
93. Ma L, Gao Y, Li BZ: Observations of the therapeutic effects of
Zhibituo for treatment of 50 patients with hyperlipidemia.
Xibei Yaoxue Zazhi 2000, 15(3):126.
94. Qiu JP, Wang ZJ, Xu XP, Ma SY, Kuang RJ: Observations of Zhi-
bituo on the therapeutic effects in treatment of 60 patients
with hyperlipidemia.  Shandong Yiyao 2002, 42(6):45-6.
95. Yang MJ, Wang RZ: Zhibituo  for treatment of 100 cases of
hyperlipidemia.  Zhongguo Xinyao Yu Linchuang Zazhi 1997,
16(1):9-10.
96. Yu HY, Li TH: Observations on the therapeutic effects of Zhi-
bituo for treatment of hyperlipidemia.  Xinxueguan Kangfu Yixue
Zazhi 1999, 8(1):30-1.
97. Chen GY: Observations on the therapeutic effects of Zhibituo
for treatment of hyperlipidemia in the elderly.  Guizhou Yiyao
1999, 23(4):307-8.
98. Chen JF, Yan ZZ, Li PT: Comparison of Zhibituo and Duoxikang
for treatment of hyperlipidemia.  Zhongguo Xinyao Yu Linchuang
Zazhi 1997, 16(1):15-17.
99. Fu G, Liu WJ, Wang GT: Comparison of Zhibituo and fish oil cap-
sules for treatment of hyperlipidemia.  Heilongjiang Yiyao 2000,
23(5):93-4.
100. Jin WQ, Li CW, Xu M, Gao YX, Xu XW: Comparison of Zhibituo
and Duoxikang in treating 108 patients with hyperlipidemia.
Zhongguo Xinyao Yu Linchuang Zazhi 1997, 16(1):61-2.
101. Li Y, Min YB, Fan XJ: Comparison of the therapeutic effects of
Zhibituo and fish oils for treatment of 30 cases of hyperlipi-
demia.  Guangdong Yaoxue Zazhi 2000, 10(1):43-5.
102. Wang LB, Qiao JJ, Li YM: Clinical evaluation of Zhibituo and con-
centrated fish oils for treatment of hyperlipidemia.  Jiamusi
Yixueyuan Xuebao 1998, 21(1):62-3.
103. Yang Q, Xue HQ: Observations on the therapeutic effects of
Zhibituo for treatment of hyperlipidemia.  Zhongguo Jiceng Yiyao
1999, 6(3):129.
104. Gu ZY, Lu ZF, Zhu HQ: Observations on the therapeutic
effects of Zhibituo for treatment of 158 patients with hyperl-
ipidemia.  Nantong Yixueyuan Xuebao 1998, 18(3):374-5.
105. Chen ZL: Controlled study of Diao Zhibituo and alginic sodium
diester for lipid lowering effect.  Henan Shiyong Shenjingbing Zazhi
1998, 1(2):20.
106. Chen L, Qin YW, Zheng X: Effects of lipid modification of Diao
Zhibituo capsules.  Zhongguo Zhongxiyi Jiehe Zazhi 2003, 23(5):389.
107. Guo XL, Li Y, Yin GN: Xuezhikang for treatment of 30 cases of
hyperlipidemia.  Ningxia Yixue Zazhi 1999, 21(7):418.
108. Lu WX, Wang JX, Zhu JG, Xu DS, Yang MJ, Wang HW, Wang RZ,
Zheng R: Zhibituo capsules in treatment of hyperlipidemia: a
multi-centre clinical trial.  Zhongguo Xinyao Yu Linchuang Zazhi
1999, 18(6):365-7.
109. Lu YS, Gu JS, Zhou WG: Comparison of the therapeutic effects
of Xuezhikang and Zhibituo in treatment of adults with hyper-
lipidemia.  Zhongguo Zhongxiyi Jiehe Zazhi 1998, 18(8):467.
110. Sun FF, Ding XF, Wang M: Comparison of lipid-lowering effects
of Xuezhikang and Zhibituo.  Jiceng Yixue Luntan 2004, 8(2):121-2.
111. Xiao CL, Yao ZQ, He SM: Comparison of the lipid modification
effects of Xuezhikang and Zhibituo for hypercholesterolemia.
Guangdong Yixue Zazhi 2000, 21(5):430-1.
112. Vickers A, Goyal N, Harland R, Rees R: Do certain countries pro-
duce only positive results? A systematic review of controlled
trials.  Contral Clin Trials 1998, 19(2):159-66.
113. Graham DJ, Staffa JA, Shatin D, Andrade SE, Schech SD, La Grenade
L, Gurwitz JH, Chan KA, Goodman MJ, Platt R: Incidence of hospi-
talized rhabdomyolysis in patients treated with lipid-lower-
ing drugs.  JAMA 2004, 292(21):2585-90.